Back to Search
Start Over
DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer
- Source :
- Frontiers in Oncology, Frontiers in Oncology, Vol 10 (2020)
- Publication Year :
- 2020
- Publisher :
- Frontiers Media SA, 2020.
-
Abstract
- To investigate the prognostic value of DGM-CM6 (Distant Genetic Model-Clinical variable Model 6) for endocrine-responsive breast cancer (ERBC) patients, we analyzed 752 operable breast cancer patients treated in a Taiwan cancer center from 2005 to 2014. Among them, 490 ERBC patients (identified by the PAM50 or immunohistochemistry method) were classified by DGM-CM6 into low- and high-risk groups (cutoff
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Multivariate analysis
lcsh:RC254-282
03 medical and health sciences
breast cancer
0302 clinical medicine
Breast cancer
endocrine-responsive
Internal medicine
medicine
Endocrine system
Lymph node
Original Research
business.industry
clinical-genomic model
Distant recurrence
Cancer
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Clinical trial
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Immunohistochemistry
distant recurrence
prognosis
business
Subjects
Details
- ISSN :
- 2234943X
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Frontiers in Oncology
- Accession number :
- edsair.doi.dedup.....1f10517078a629578e5f0836db922b5f